

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE

This announcement is made by the board of directors (the “**Board**”) of Brii Biosciences Limited (the “**Company**”) on a voluntary basis.

The Board is pleased to announce that the Company will be included in the MSCI China Small Cap Index as a constituent, with effect after market close on May 31, 2022.

The MSCI China Small Cap Index is an equity index compiled by MSCI Inc. (“**MSCI**”), a leading provider of critical decision support tools and services for the global investment community. The index is designed to measure the performance of the China market’s small-cap segment and is widely recognized by the international financial community, as a benchmark for global institutional investors seeking to optimize their investment portfolios. The Company was selected to be included in this index following the May 2022 Semi-Annual Index Review for the MSCI Equity Indexes.

Dr. Ankang Li, the Chief Financial Officer and the Strategy Officer of the Company, commented, “becoming a constituent of the MSCI China Small Cap Index is another significant capital markets milestone for the Company, following our inclusion in the Hang Seng Composite Index and the Shenzhen-Hong Kong Stock Connect program last year. Being among the few biotech stocks included in one of the most influential China-focused indexes in the global capital markets demonstrates our growing visibility and recognition by the global investor community. We look forward to continuing to deliver shareholders’ value by developing innovative therapies for diseases around the world with significant unmet medical needs and large public health burdens.”

Cautionary Statement: Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. When in doubt, shareholders of the Company and potential investors are advised to seek advice from professional or financial advisers.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, May 25, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive directors.